Elicio Therapeutics Inc (ELTX) - News Archive

: This article delves into the recent developments and promising advancements announced by Elicio Therapeutics, a clinical-stage biotechnology leader in cancer immunotherapy. By examining the emerging data from their on...

Elicio Therapeutics Solidifies Financial Footing with $10 Million Registered Direct Offering and Strategic Talent Acquisition BOSTON, Jan. 30, 2025 Elicio Therapeutics, Inc. (Nasdaq: ELTX), a pioneering clinical-stage b...

Elicio Therapeutics Promising Outlook Amidst Competitive Financial Landscape: A Look at the ELI-002 Phase 1 AMPLIFY-201 Study Results Elicio Therapeutics, a company at the forefront of innovation in cancer treatment, re...

Targeted Immunotherapy Progress: Elicio Therapeutics ELI-002 Demonstrates Promising Results in Combating KRAS Mutations At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, Elicio Therapeutics shared c...

Harnessing Talent: Elicio Therapeutics Strategic Use of Inducement Stock Options Amidst a Surge in Market ValuationIn the dynamic landscape of biotechnology, attracting and retaining top talent is paramount for innovati...

Elicio Therapeutics Announces Inducement Grants for New EmployeeBoston, Sept. 17, 2024 Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio), a clinical-stage biotechnology company at the forefront of...

Elicio Therapeutics Secures $20 Million in Private Placement for Cancer Treatment ResearchBOSTON, Aug. 12, 2024 - Elicio Therapeutics, a leading biotechnology company focused on developing innovative immunotherapies for...

Protagenic Therapeutics Stock (PTIX) and Elicio Therapeutics Inc. (ELTX): A Comparative Analysis In the ever-evolving world of pharmaceuticals and biotechnology, investors are constantly on the lookout for promising com...

Elicio Therapeutics, a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, has seen its shares perform strongly in the current year. Despite recent fluctuations, the co...

Elicio Therapeutics, a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, has announced the pricing of an underwritten public offering worth approximately $11.5 million. The...

BOSTON, June 27, 2024 - Elicio Therapeutics, Inc. (Nasdaq: ELTX) has taken a significant step towards advancing its clinical-stage biotechnology portfolio with the announcement of a proposed public offering. As a pionee...

Elicio Therapeutics: Unveiling Promising Innovations in Cancer Immunotherapy Elicio Therapeutics, Inc., a clinical-stage biotechnology company (Nasdaq: ELTX), has announced a series of promising developments in their pu...

Elicio Therapeutics Boosts Team with Inducement Grants to Support Cancer Immunotherapy DevelopmentBOSTON, June 18, 2024 - Elicio Therapeutics, Inc. (Nasdaq: ELTX) continues to strengthen its position in developing innov...

Elicio Therapeutics, a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment, presented preliminary data from their ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P at...

Elicio Therapeutics to Present Promising Clinical and Preclinical Data on Immunotherapies at AACR Annual MeetingBOSTON, April 05, 2024 - Elicio Therapeutics, a pioneering biotechnology company focused on developing inno...

Elicio Therapeutics Announces $6.0 Million Private Placement Financing: Expanding the Reach of Novel Cancer ImmunotherapiesBOSTON, March 18, 2024 - Elicio Therapeutics, a clinical-stage biotechnology company focused on...

:Elicio Therapeutics, a clinical-stage biotechnology company, has recently published compelling preclinical data in Cancer Immunology Research, showcasing the potential of their proprietary AMP lymph node-targeting immu...

BOSTON, Dec. 22, 2023 - Elicio Therapeutics, Inc. (Nasdaq: ELTX), a leading clinical-stage biotechnology company specializing in developing immunotherapies for cancer treatment, announced today the execution of a subscr...